Valuation : Erasca, Inc.

Market Cap 5.73B 4.93B 4.62B 4.23B 7.9B 541B 7.95B 54.58B 21.26B 277B 21.5B 21.03B 892B P/E 2026 *
-16.7x
P/E 2027 * -26.1x
Enterprise Value 4.88B 4.2B 3.94B 3.61B 6.73B 461B 6.77B 46.49B 18.11B 236B 18.31B 17.91B 760B EV / Sales 2026 *
-
EV / Sales 2027 * -
Free-Float
90.52%
Yield 2026 *
-
Yield 2027 * -
1 day-0.67%
1 week-15.09%
Current month-9.06%
1 month-10.41%
3 months+20.62%
6 months+11.91%
Current year+337.10%
1 week 15.78
Extreme 15.78
19.59
1 month 15.78
Extreme 15.78
20.4
Current year 3.36
Extreme 3.36
24.28
1 year 1.4
Extreme 1.405
24.28
3 years 1.01
Extreme 1.01
24.28
5 years 1.01
Extreme 1.01
24.47
10 years 1.01
Extreme 1.01
24.47
Manager TitleAgeSince
Chief Executive Officer 54 01/03/2019
Director of Finance/CFO 43 07/01/2021
Chief Tech/Sci/R&D Officer - 25/05/2022
Director TitleAgeSince
Chairman 54 01/10/2018
Director/Board Member 79 01/06/2018
Director/Board Member 58 02/07/2018
Date Insider Type Main position Quantity % Market Cap. Importance
10/08/26 Free

Chief Technology Officer

1,300,000 0.3745%
26/06/26 Free

Director

29,888 0.0096%
01/04/26 Exercice

General Counsel

240,000 0.0772%
Change 5-day change 1-year change 3-year change Capi.($)
-0.67%-15.09%+916.25%+527.80% 5.73B
-0.24%-0.99%+3.26%+18.17% 50.14B
+0.78%-2.12%+433.44%+501.63% 44.85B
+2.95%+3.87%+47.83%+21.08% 43.43B
+0.25%-3.49%+9.23%+73.60% 41.14B
+0.43%-3.26%+14.75%+49.08% 32.92B
+1.43%+8.34% - - 17.56B
+0.06%-4.15%+25.36%+116.96% 16.55B
+0.93%+0.88%+19.64%+29.70% 14.65B
+0.54%-0.59%+81.92%+39.94% 13.93B
Average +0.65%-2.14%+172.41%+153.11% 28.09B
Weighted average by Cap. +0.78%-1.40%+112.56%+132.59%

Financials

2026 *2027 *
Net sales - -
Net income -319M -274M -257M -236M -439M -30.1B -443M -3.04B -1.18B -15.43B -1.2B -1.17B -49.66B -218M -188M -176M -161M -301M -20.63B -303M -2.08B -811M -10.57B -820M -802M -34.03B
Net Debt -849M -730M -685M -627M -1.17B -80.17B -1.18B -8.09B -3.15B -41.08B -3.19B -3.12B -132B -762M -655M -615M -563M -1.05B -71.97B -1.06B -7.26B -2.83B -36.88B -2.86B -2.8B -119B
Logo Erasca, Inc.
Erasca, Inc. is a clinical-stage precision oncology company. The Company is focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The Company has assembled RAS/MAPK pathway-focused pipeline in the industry, consisting of modality-agnostic programs aligned with its three therapeutic strategies of: targeting key upstream and downstream signaling nodes in the RAS/MAPK pathway; targeting RAS directly; and targeting escape routes that emerge in response to treatment. Its pipeline includes one clinical-stage program (a pan-RAF inhibitor), two IND-enabling stage programs (a pan-RAS molecular glue and a pan-KRAS inhibitor), and an additional discovery-stage program (an EGFR D2/D3 biparatopic antibody). Its lead product candidate is naporafenib, the Company initiated its SEACRAFT-2 pivotal Phase III trial for patients with NRAS-mutated (NRASm) melanoma.
Employees
103
Date Price Change Volume
03/09/26 $16.26 -0.67% 3,761,098
02/09/26 $16.37 -2.33% 5,121,428
01/09/26 $16.76 -6.26% 6,708,100
31/08/26 $17.88 -0.83% 4,766,259
28/08/26 $18.03 -7.49% 2,887,576
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
B
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
16.37USD
Average target price
24.30USD
Spread / Average Target
+48.44%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. ERAS Stock